2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2357

Reactions to Online Testimonials: A Cluster Analysis of Risk Perception and Decision Making
Abstract Number: 459

Readmission Rate within 30 Days of Hospitalization Due to New Onset Lupus Nephritis and Associated Risk Factors: The Importance of Intravenous Pulse Methylprednisolone Therapy
Abstract Number: 688

Real Life Analysis of a Latin America Tertiary Spondyloarthritis Single-Center: High Frequency of Peripheral Involvement and Use of Synthetic Dmard
Abstract Number: 2490

Real World Evidence Describing Infliximab Utilization Patterns in Rheumatoid Arthritis Patients in Community Rheumatology Practices in the United States: Implications for Cost Efficiencies?
Abstract Number: 2658

Real World Medication Use in Incident Systemic Lupus Erythematosus and Lupus Nephritis Patients
Abstract Number: 645

Real World Secukinumab Study in Ankylosing Spondylitis and Psoriatic Arthritis – Comorbidities and Extraarticular Manifestations: Incidence and Status throughout a Non-Interventional Study in Germany
Abstract Number: 1542

Real-World Data from a Post-Approval Safety Surveillance Study of Tofacitinib Vs Biologic Dmards and Conventional Synthetic Dmards: Five-Year Results from a US-Based Rheumatoid Arthritis Registry
Abstract Number: 2138

Real-World Evaluation of Treatment Patterns of Methotrexate Users in Psoriatic Arthritis
Abstract Number: 598

Real-World Experience of Effectiveness and Safety of Certolizumab Pegol for Rheumatoid Arthritis in Japan: Single-Center Retrospective Study
Abstract Number: 1624

Real-World Insight into the Disease Burden and Treatment of Spondyloarthritis from a US-Based Life Impact Survey
Abstract Number: 2596

Real-World Long-Term Effectiveness of Switching between Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register
Abstract Number: 2486

Real-World Outcomes Associated with Triple Therapy Vs. TNFi Combo Therapy: Results from the Corrona Registry
Abstract Number: 2382

Real-World Safety and Effectiveness of Adalimumab in Patients with Juvenile Idiopathic Arthritis: Results from a Post-Marketing Surveillance in Japan
Abstract Number: 2591

Real-World Use of Secukinumab in Axial Spondyloarthritis: First Year Data from the Czech National Registry
Abstract Number: 2592

Real-World Use of Secukinumab in Psoriatic Arthritis: First Year Data from the Czech National Registry

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].